PMID- 36579506
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230103
IS  - 2075-4426 (Print)
IS  - 2075-4426 (Electronic)
IS  - 2075-4426 (Linking)
VI  - 12
IP  - 11
DP  - 2022 Oct 27
TI  - Anti-TNFalpha Drugs and Interleukin Inhibitors: Epidemiological and Pharmacovigilance 
      Investigation in COVID-19 Positive Patients.
LID - 10.3390/jpm12111770 [doi]
LID - 1770
AB  - Cytokine patterns and immune activation in patients with Coronavirus 2019 
      (COVID-19) seem to resemble the case of rheumatoid arthritis (RA), psoriasis and 
      inflammatory bowel disease (IBD). Biological drugs, such as anti-tumor necrosis 
      factor alpha (TNFalpha) and interleukin (IL) inhibitors, appear to be protective against 
      adverse outcomes of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). 
      However, these treatments are associated with an increased risk of secondary 
      infections. The aim of the study was to examine the association between the use 
      of immunomodulatory drugs and the risk of SARS-CoV-2-associated positivity, 
      hospitalization and death compared to other commonly prescribed treatment 
      regimens among patients with immune-mediated inflammatory diseases. METHODS: All 
      patients with RA, Psoriasis and IBD were included in this observational analysis 
      and treated with anti-TNFalpha, IL-inhibitors, Methotrexate (MTX) and Sulfasalazine 
      drugs during the year 2020-2021. The population consisted of 932 patients and 
      demographic, clinical and pharmacological data were analyzed. RESULTS: Although 
      no significant differences were observed between patients treated with biological 
      and synthetic drugs in terms of hospitalization and death, the multivariate 
      logistic model showed that the type of drug influences the possibility of 
      COVID-19 positivity. CONCLUSIONS: The results of this analysis support the use of 
      biological drugs and justify further research investigating the association of 
      these biological therapies with COVID-19 outcomes.
FAU - Maraia, Zaira
AU  - Maraia Z
AD  - San Benedetto del Tronto Hospital Pharmacy, ASUR Marche AV5, 63074 San Benedetto 
      del Tronto, Italy.
FAU - Mazzoni, Tony
AU  - Mazzoni T
AD  - Department of Pharmacology, University of Camerino, 62032 Camerino, Italy.
FAU - Rocchi, Marco Bruno Luigi
AU  - Rocchi MBL
AUID- ORCID: 0000-0002-0056-5795
AD  - Department of Biomolecular Sciences, University of Urbino, 61020 Urbino, Italy.
FAU - Feliciani, Denise
AU  - Feliciani D
AD  - Ascoli Piceno Hospital Pharmacy, ASUR Marche AV5, 63100 Ascoli Piceno, Italy.
FAU - Romani, Maria Chiara
AU  - Romani MC
AD  - San Benedetto del Tronto Hospital Pharmacy, ASUR Marche AV5, 63074 San Benedetto 
      del Tronto, Italy.
FAU - Acciarri, Giovanna
AU  - Acciarri G
AD  - San Benedetto del Tronto Hospital Pharmacy, ASUR Marche AV5, 63074 San Benedetto 
      del Tronto, Italy.
FAU - Rafaiani, Stefania
AU  - Rafaiani S
AD  - Ascoli Piceno Hospital Pharmacy, ASUR Marche AV5, 63100 Ascoli Piceno, Italy.
FAU - Mazzoni, Isidoro
AU  - Mazzoni I
AD  - Ascoli Piceno Hospital Pharmacy, ASUR Marche AV5, 63100 Ascoli Piceno, Italy.
LA  - eng
PT  - Journal Article
DEP - 20221027
PL  - Switzerland
TA  - J Pers Med
JT  - Journal of personalized medicine
JID - 101602269
PMC - PMC9698457
OTO - NOTNLM
OT  - COVID-19
OT  - IL-inhibitors
OT  - SARS-CoV-2
OT  - anti-TNFalpha
OT  - death
OT  - hospitalization
OT  - inflammatory bowel disease
OT  - positivity
OT  - psoriasis
OT  - rheumatoid arthritis
COIS- The authors declare no conflict of interest.
EDAT- 2022/12/30 06:00
MHDA- 2022/12/30 06:01
PMCR- 2022/10/27
CRDT- 2022/12/29 04:14
PHST- 2022/09/09 00:00 [received]
PHST- 2022/10/19 00:00 [revised]
PHST- 2022/10/24 00:00 [accepted]
PHST- 2022/12/29 04:14 [entrez]
PHST- 2022/12/30 06:00 [pubmed]
PHST- 2022/12/30 06:01 [medline]
PHST- 2022/10/27 00:00 [pmc-release]
AID - jpm12111770 [pii]
AID - jpm-12-01770 [pii]
AID - 10.3390/jpm12111770 [doi]
PST - epublish
SO  - J Pers Med. 2022 Oct 27;12(11):1770. doi: 10.3390/jpm12111770.